Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer:a randomized,non-inferiority,multicenter trial  

作　　者：Danhui Weng Huihua Xiong Changkun Zhu Xiaoyun Wan Yaxia Chen Xinyu Wang Youzhong Zhang Jie Jiang Xi Zhang Qinglei Gao Gang Chen Hui Xing Changyu Wang Kezhen Li Yaheng Chen Yuyan Mao Dongxiao Hu Zimin Pan Qingqin Chen Baoxia Cui Kun Song Cunjian Yi Guangcai Peng Xiaobing Han Ruifang An Liangsheng Fan Wei Wang Tingchuan Xiong Yile Chen Zhenzi Tang Lin Li Xingsheng Yang Xiaodong Cheng Weiguo Lu Hui Wang Beihua Kong Xing Xie Ding Ma 

机构地区：[1]Department of Obstetrics and Gynecology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [3]Department of Gynecologic Oncology,Women’s Hospital,School of Medicine,Zhejiang University,Hangzhou 310006,China [4]Department of Obstetrics and Gynecology,Qilu Hospital,Shandong University,Jinan 250012,China [5]Department of Obstetrics and Gynecology,Xiangyang Central Hospital,Hubei University of Arts and Science,Xiangyang 441021,China [6]Department of Obstetrics and Gynecology,The First Affiliated Hospital of Yangtze University,Jingmen 448000,China [7]Department of Obstetrics and Gynecology,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China [8]Department of Obstetrics and Gynecology,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China [9]Department of Gynecologic Oncology,Affiliated Tumour Hospital,Xinjiang Medical University,Urumqi 830000,China [10]Department of Gynecologic Oncology,Hunan Province Tumor Hospital,Changsha 410013,China

出　　处：《Frontiers of Medicine》2023年第1期93-104,共12页医学前沿（英文版）

基　　金：National Natural Science Foundation of China (Nos. 81630060, 81230038, 81372805, and 81472444);National Key Research & Development Program of China (No. 2016YFC0902900);Bristol-Myers Squibb CA139-702 and the National Science-technology Supporting Plan Projects (No.2015BAI13B05).

摘　　要：We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415–1.757;P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment.

关 键 词：CHEMOTHERAPY cervical cancer lymph node metastasis concurrent chemoradiotherapy quality of life 

分 类 号：R737.33[医药卫生—肿瘤]